Topics:

Phase II trials planned for oral methylnaltrexone for chronic pain

Phase II trials planned for oral methylnaltrexone for chronic pain

COLLEGEVILLE, Pennsylvania—Wyeth Pharmaceuticals and Progenics plan to initiate two 4-week phase II clinical trials to evaluate daily dosing of oral methylnaltrexone in patients with chronic, nonmalignant pain who are experiencing opioid-induced constipation (OIC). An NDA for the subcutaneous formulation has been filed with FDA for the treatment of OIC in the end-of-life setting.

 
Loading comments...
Please Wait 20 seconds or click here to close